Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis

T. Enomoto, Yukihiro Noda, Toshitaka Nabeshima

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

In humans, phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, PCP-treated animals have been utilized as an animal model of schizophrenia. PCP-treated animals exhibit hyperlocomotion as an index of positive symptoms, and a social behavioral deficit in a social interaction test and enhanced immobility in a forced swimming test as indices of negative symptoms. They also show a sensorimotor gating deficit and cognitive dysfunctions in several learning and memory tests. Some of these behavioral changes endure after withdrawal from repeated PCP treatment. Furthermore, repeated PCP treatment induces some neurochemical and neuronanatomical changes. Recently, genetic approaches based on "the glutamate hypothesis of schizophrenia" have been used to develop animal models of schizophrenia. NMDA receptor subunit ζ1 knockdown, ε1 knockout (KO) and ζ1 point mutant mice exhibiting a hypofunction of NMDA receptors show hyperlocomotion, social behavioral deficit, sensorimotor gating deficit or cognitive dysfunction. Forebrain-specific calcineurin KO, neuregulin 1 heterozygous KO and lysophosphatidic acid 1 receptor KO mice can also serve as animal models of schizophrenia. These findings suggest that PCP and genetic animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.

Original languageEnglish
Pages (from-to)291-301
Number of pages11
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume29
Issue number4
DOIs
Publication statusPublished - 01-05-2007
Externally publishedYes

Fingerprint

Phencyclidine
Genetic Models
Glutamic Acid
Schizophrenia
Animal Models
N-Methyl-D-Aspartate Receptors
Sensory Gating
Lysophosphatidic Acid Receptors
Neuregulin-1
Calcineurin
Interpersonal Relations
Prosencephalon
Knockout Mice
Psychotic Disorders
Learning
Cognitive Dysfunction

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{d5cf0c866def4579a40f0fb4a4f82a41,
title = "Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis",
abstract = "In humans, phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, PCP-treated animals have been utilized as an animal model of schizophrenia. PCP-treated animals exhibit hyperlocomotion as an index of positive symptoms, and a social behavioral deficit in a social interaction test and enhanced immobility in a forced swimming test as indices of negative symptoms. They also show a sensorimotor gating deficit and cognitive dysfunctions in several learning and memory tests. Some of these behavioral changes endure after withdrawal from repeated PCP treatment. Furthermore, repeated PCP treatment induces some neurochemical and neuronanatomical changes. Recently, genetic approaches based on {"}the glutamate hypothesis of schizophrenia{"} have been used to develop animal models of schizophrenia. NMDA receptor subunit ζ1 knockdown, ε1 knockout (KO) and ζ1 point mutant mice exhibiting a hypofunction of NMDA receptors show hyperlocomotion, social behavioral deficit, sensorimotor gating deficit or cognitive dysfunction. Forebrain-specific calcineurin KO, neuregulin 1 heterozygous KO and lysophosphatidic acid 1 receptor KO mice can also serve as animal models of schizophrenia. These findings suggest that PCP and genetic animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.",
author = "T. Enomoto and Yukihiro Noda and Toshitaka Nabeshima",
year = "2007",
month = "5",
day = "1",
doi = "10.1358/mf.2007.29.4.1075358",
language = "English",
volume = "29",
pages = "291--301",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "4",

}

Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. / Enomoto, T.; Noda, Yukihiro; Nabeshima, Toshitaka.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 29, No. 4, 01.05.2007, p. 291-301.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis

AU - Enomoto, T.

AU - Noda, Yukihiro

AU - Nabeshima, Toshitaka

PY - 2007/5/1

Y1 - 2007/5/1

N2 - In humans, phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, PCP-treated animals have been utilized as an animal model of schizophrenia. PCP-treated animals exhibit hyperlocomotion as an index of positive symptoms, and a social behavioral deficit in a social interaction test and enhanced immobility in a forced swimming test as indices of negative symptoms. They also show a sensorimotor gating deficit and cognitive dysfunctions in several learning and memory tests. Some of these behavioral changes endure after withdrawal from repeated PCP treatment. Furthermore, repeated PCP treatment induces some neurochemical and neuronanatomical changes. Recently, genetic approaches based on "the glutamate hypothesis of schizophrenia" have been used to develop animal models of schizophrenia. NMDA receptor subunit ζ1 knockdown, ε1 knockout (KO) and ζ1 point mutant mice exhibiting a hypofunction of NMDA receptors show hyperlocomotion, social behavioral deficit, sensorimotor gating deficit or cognitive dysfunction. Forebrain-specific calcineurin KO, neuregulin 1 heterozygous KO and lysophosphatidic acid 1 receptor KO mice can also serve as animal models of schizophrenia. These findings suggest that PCP and genetic animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.

AB - In humans, phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, PCP-treated animals have been utilized as an animal model of schizophrenia. PCP-treated animals exhibit hyperlocomotion as an index of positive symptoms, and a social behavioral deficit in a social interaction test and enhanced immobility in a forced swimming test as indices of negative symptoms. They also show a sensorimotor gating deficit and cognitive dysfunctions in several learning and memory tests. Some of these behavioral changes endure after withdrawal from repeated PCP treatment. Furthermore, repeated PCP treatment induces some neurochemical and neuronanatomical changes. Recently, genetic approaches based on "the glutamate hypothesis of schizophrenia" have been used to develop animal models of schizophrenia. NMDA receptor subunit ζ1 knockdown, ε1 knockout (KO) and ζ1 point mutant mice exhibiting a hypofunction of NMDA receptors show hyperlocomotion, social behavioral deficit, sensorimotor gating deficit or cognitive dysfunction. Forebrain-specific calcineurin KO, neuregulin 1 heterozygous KO and lysophosphatidic acid 1 receptor KO mice can also serve as animal models of schizophrenia. These findings suggest that PCP and genetic animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=34547634946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547634946&partnerID=8YFLogxK

U2 - 10.1358/mf.2007.29.4.1075358

DO - 10.1358/mf.2007.29.4.1075358

M3 - Review article

VL - 29

SP - 291

EP - 301

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 4

ER -